Background: Unnecessary intervention and overtreatment of indolent
disease are common challenges in clinical management of prostate cancer.
Improved tools to distinguish lethal from indolent disease are critical.
Methods: We performed a genome-wide survival analysis of cause-specific
death in 24,023 prostate cancer patients (3,513 disease-specific deaths)
from the PRACTICAL and BPC3 consortia. Top findings were assessed for
replication in a Norwegian cohort (CONOR).
Results: We observed no significant association between genetic variants
and prostate cancer survival.
Conclusions: Common genetic variants with large impact on prostate
cancer survival were not observed in this study.
Impact: Future studies should be designed for identification of rare
variants with large effect sizes or common variants with small effect
sizes. (C) 2015 AACR
